International Biotechnology (LON:IBT) Stock Price Passes Above 200-Day Moving Average - Time to Sell?

Key Points

• Technical breakout: International Biotechnology's shares rose above their 200-day moving average (200‑day MA GBX 924.82), trading as high as GBX 990 and last at GBX 979.34 on volume of 34,546 shares.
• Valuation and risk profile: The trust has a market cap of £310.31 million, a negative PE ratio (-295.65) and a low beta (0.49), implying current losses and lower volatility versus the market.
• Investment focus: The company targets long-term capital growth through a diversified portfolio of biotechnology, life sciences, medical device and healthcare services companies, both quoted and unquoted.

International Biotechnology (LON:IBT - ) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 924.82 and traded as high as GBX 990. International Biotechnology shares last traded at GBX 979.34, with a volume of 34,546 shares.

International Biotechnology Trading Down 0.4%

The firm has a fifty day moving average of GBX 927.99 and a two-hundred day moving average of GBX 924.82. The company has a market cap of £310.31 million, a PE ratio of -295.65 and a beta of 0.49.

About International Biotechnology

The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. Investments may also be made in related sectors such as medical devices and healthcare services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.